Tipiracil, an uracil derivative, is a thymidine phosphorylase inhibitor. It is an FDA-approved drug used with trifluridine to treat metastatic colorectal and gastric cancer. Previously, tipiracil has been reported to form hydrogen bonds with SARS-CoV-2 NSP15 active site residues Ser 294, Lys345, and His250 . Tipiracil suppresses RNA nuclease activity of NSP15 and modestly inhibits SARS-CoV-2 virus replication in vitro without affecting viability of host cells most likely through competitive inhibition . Moreover, recent in-silico-based approaches have identified other potential NSP15 inhibitors that await further structural and biochemical validation . The current COVID-19 pandemic brought attention to the repurposing of existing drugs and the rapid identification of candidate compounds. In this study, we use structure-based pharmacophore model and molecular docking to identify potential inhibitors of NSP15 by screening FDA approved drug database.